Mesenchymal Stem Cell Therapy for Airway Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current asthma therapies, including corticosteroids and β-agonists, primarily manage symptoms rather than address the underlying pathogenesis of allergic airways disease (AAD)/asthma, and are ineffective for severe and refractory asthma populations, with persistent airway inflammation and remodelling contributing to disease progression and complications.
Innovation Solution
Administration of mesenchymoangioblast mesenchymal stem cells (MCA-MSCs) expressing specific microRNAs (miR-145-5p, miR-181b-5p, and miR-214-3p, but not miR-127-3p and miR-299-5p, which are cultured under specific conditions to exhibit a defined phenotype, providing immunomodulatory and anti-inflammatory effects to reduce airway inflammation, remodelling, and hyperresponsiveness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If corticosteroids are used to treat asthma, then airway inflammation is suppressed, but systemic side effects occur and lung function is not improved in severe refractory cases
Solution Approach 1:
The patent uses mesenchymal stem cells (MSCs) as intermediary agents that mediate the treatment of airway inflammation. These cells are administered systemically and home to the injured airway tissue through chemokine receptor expression, where they exert anti-inflammatory effects locally without requiring high doses of corticosteroids that cause systemic side effects. The MSCs act as a bridge between systemic administration and localized therapeutic action.
Solution Approach 2:
The patent changes the therapeutic parameter from chemical anti-inflammatory agents (corticosteroids) to cellular therapy (MSCs). This parameter change allows for targeted delivery of anti-inflammatory effects to the airway tissue while avoiding the systemic circulation effects that cause harmful side effects. The MSCs can be cultured and expanded to provide sufficient numbers for treatment.
2Ease of operation
If β-agonists are used for symptom relief, then asthma symptoms are managed, but underlying airway inflammation persists and disease progression occurs
Solution Approach 1:
The patent introduces MSCs as intermediary cells that can address the underlying disease pathology rather than just symptoms. These cells home to inflamed airway tissue and modulate the immune response, reducing airway inflammation and preventing disease progression. The MSCs provide a bridge between symptomatic management and disease-modifying therapy.
3Object-affected harmful factors
If high doses of corticosteroids are administered to severe asthmatic subjects, then inflammation is suppressed, but lung function and quality of life do not improve
Solution Approach 1:
The patent uses MSCs as intermediary cells that can suppress airway inflammation through direct cell-cell contact and secretion of anti-inflammatory factors at the site of injury. This localized action is more effective than systemic corticosteroids for improving lung function, as the cells directly interact with the inflamed tissue and promote repair mechanisms.
Solution Approach 2:
The patent employs the body's own regenerative capacity by using MSCs that can differentiate and promote tissue repair. These cells stimulate endogenous repair mechanisms, leading to actual improvement in lung function and quality of life rather than just temporary suppression of inflammation symptoms.
4Area of stationary object
If MSCs are administered systemically via IV infusion, then broad distribution is achieved, but consistent relief of adverse symptoms is not demonstrated
Solution Approach 1:
The patent uses MSCs with specific chemokine receptor expression as intermediaries that actively home to sites of airway injury and inflammation. This targeted homing mechanism ensures that the cells concentrate where needed in the lungs, providing consistent therapeutic effects. The cells can be cultured and expanded to ensure sufficient numbers are available for treatment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
MCA-MSCs significantly reduce airway inflammation, fibrosis, and hyperresponsiveness, offering a safe and effective treatment for AAD/asthma, potentially replacing the need for combination therapies and providing a continuous supply through iPSC-derived cells, with no adverse effects on basal parameters.
Implementation Method 1
MSCs also home to the injured tissue through the expression of the chemokine receptor type 4, expression of which is heightened in a pro-inflammatory environment, as in asthma, enhancing their homing ability.
Implementation Method 2
MSCs exhibit immunomodulatory and anti-inflammatory properties through both direct cell-cell contact and secretion of paracrine factors.
Implementation Method 3
MSCs have been shown to actively reduce the presence and activity of the cells responsible for inflammation. Furthermore, MSC treatment has been shown to reduce epithelial thickness, smooth muscle hyperplasia and goblet cell metaplasia in the airways, and modestly decrease sub-epithelial and total collagen deposition (fibrosis) through their ability to promote collagen-degrading gelatinase levels
Data Source
Figure 1A~2B
Figure 3A~3C
Figure 4~6B
AI summary
The invention relates to use of a mesenchymoangioblast-derived mesenchymal stem cell (MSC-MSC) for treating allergic airway disease (AAD)/ asthma in a subject.